ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02060162 (Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA)
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis.Liver international : official journal of the International Association for the Study of the Liver · 2021Pooled it
- Immunological Efficacy of Tenofovir Disproxil Fumarate-Containing Regimens in Patients With HIV-HBV Coinfection: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase.AIDS research and therapy · 2026Trial
- The HIV/HBV Co‑infection Paradox: Immune Modulation Amid Persistent Risk [Response To Letter].Infection and drug resistance · 2026Article
- The Role of Liver Biopsy and Fine Needle Aspiration in Novel HBV Therapeutics in HIV and HBV Coinfection.Current HIV/AIDS reports · 2025Review
- Hepatitis B surface antigen is upregulated by HIV Tat in an HIV-hepatitis B virus co-infection model system.Microbiology spectrum · 2025Article
- Prevalence, associated factors, and viral load dynamics of hepatitis B virus infection among HIV patients in three healthcare facilities of South Kivu province, eastern Democratic Republic of Congo : Chronic hepatitis B virus among HIV patients in South Kivu province.BMC infectious diseases · 2025Article
- Impact of Socio-Economic, Behavioural and Clinical Factors on Liver Disease Progression in Individuals With HIV and Hepatitis B.Liver international : official journal of the International Association for the Study of the Liver · 2025Observational
- Patterns of liver fibrosis evolution in Chinese HIV/HBV co-infected adults following 5-year antiretroviral treatment: A longitudinal study using non-invasive APRI and Fib-4 scores.Virologica Sinica · 2025Article
- New Window Into Hepatitis B in Africa: Liver Sampling Combined With Single-Cell Omics Enables Deep and Longitudinal Assessment of Intrahepatic Immunity in Zambia.The Journal of infectious diseases · 2024Article
- Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study.Journal of the International AIDS Society · 2024Article
- Strategies for Hepatitis B Virus Prevention in People Living with HIV.Current HIV/AIDS reports · 2023Review
- Chronic hepatitis B and HIV coinfection.Topics in antiviral medicine · 2023Review
- Prevalence and Predictors of Liver Fibrosis in People Living with Hepatitis B in Senegal.Viruses · 2022Article
- Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.AIDS (London, England) · 2022Article
- Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome.World journal of gastroenterology · 2022Article
- Screening for hepatocellular carcinoma among adults with HIV/HBV co-infection in Zambia: a pilot study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Liver fibrosis progression in a cohort of young HIV and HIV/ HBV co-infected patients: A longitudinal study using non-invasive APRI and Fib-4 scores.Frontiers in medicine · 2022Article
- Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal.Journal of viral hepatitis · 2022Article
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
12 authors at 9 institutions in 4 countries.
Funding
Abstract
backgroundWe investigated changes in hepatic fibrosis, based on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in Zambia.
methodsPatients' liver stiffness measurements (LSM; kiloPascals [kPa]) at ART initiation were categorized as no or minimal fibrosis (equivalent to Metavir F0-F1), significant fibrosis (F2-F3), and cirrhosis (F4). TE was repeated following 1 year of ART. Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM change and the proportion with an increase/decrease in fibrosis category. Using multivariable logistic regression, we assessed correlates of significant fibrosis/cirrhosis at 1 year on ART.
resultsAmong 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recommended first-line treatment. The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% (P < .001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 year (all P < .05).
conclusionThe percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant fibrosis/cirrhosis decreased following ART initiation-regardless of HBV status. This suggests that HIV infection plays a role in liver inflammation. HBV-coinfected patients were more likely to have significant fibrosis/cirrhosis at 1 year on ART. CLINICAL TRIALS REGISTRATION: NCT02060162.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.